Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...
Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Thursday, March 13th. HC Wainwright ...
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market ...
Zacks Investment Research on MSN5d
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock UpNektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks ...
Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...
5d
Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...
Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...
Reports Q4 revenue $29.2M, consensus $36.66M. “The significant progress we made last year in advancing our immunology pipeline positions us for ...
Nektar Therapeutics (NKTR) came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results